About the Authors
- Patrizia Fabbi
-
Affiliation Research Center of Cardiovascular Biology, Department of Internal Medicine, University of Genova, Genova, Italy
- Paolo Spallarossa
-
Affiliation Research Center of Cardiovascular Biology, Department of Internal Medicine, University of Genova, Genova, Italy
- Silvano Garibaldi
-
Affiliation Research Center of Cardiovascular Biology, Department of Internal Medicine, University of Genova, Genova, Italy
- Chiara Barisione
-
Affiliation Research Center of Cardiovascular Biology, Department of Internal Medicine, University of Genova, Genova, Italy
- Marzia Mura
-
Affiliation Research Center of Cardiovascular Biology, Department of Internal Medicine, University of Genova, Genova, Italy
- Paola Altieri
-
Affiliation Research Center of Cardiovascular Biology, Department of Internal Medicine, University of Genova, Genova, Italy
- Barbara Rebesco
-
Affiliation Antiblastic Drug Unit, IRCCS AOU San Martino-IST, Genova, Italy
- Maria Gaia Monti
-
Affiliation Department of Medical Translational Sciences, University of Napoli Federico II, Napoli, Italy
- Marco Canepa
-
Affiliation Research Center of Cardiovascular Biology, Department of Internal Medicine, University of Genova, Genova, Italy
- Giorgio Ghigliotti
-
Affiliation Research Center of Cardiovascular Biology, Department of Internal Medicine, University of Genova, Genova, Italy
- Claudio Brunelli
-
Affiliation Research Center of Cardiovascular Biology, Department of Internal Medicine, University of Genova, Genova, Italy
- Pietro Ameri
-
* E-mail: pietroameri@unige.it
Affiliation Research Center of Cardiovascular Biology, Department of Internal Medicine, University of Genova, Genova, Italy
Competing Interests
The authors have declared that no competing interests exist.
Author Contributions
Conceived and designed the experiments: PF PS SG MC BC PA. Performed the experiments: PF SG CB MM PA BR GG PA MGM. Analyzed the data: PF SG MC PA MGM. Contributed reagents/materials/analysis tools: BR. Wrote the paper: PF SG PA. Revised the manuscript for important intellectual content: PS CB MM PA BR MC GG BC. Final approval of the version to be published: PF PS SG CB MM PA BR MC GG BC PA MGM.